Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous Tumor
Rainer Hamacher(Essen University Hospital), Wolfgang P. Fendler(Essen University Hospital), Ken Herrmann(Essen University Hospital), Christoph E. Heilig(German Cancer Research Center), Benedikt M. Schaarschmidt(Essen University Hospital), Karina Kostbade(German Cancer Research Center), Pedro Fragoso Costa(Essen University Hospital), Sebastian Bauer(Science for Life Laboratory), Sven‐Thorsten Liffers(German Cancer Research Center), Martin Schüler(German Cancer Research Center), Sabrina Borchert(Essen University Hospital), Hans‐Ulrich Schildhaus(University of Kassel), Lale Umutlu(Essen University Hospital), Kim M. Pabst(West German Heart and Vascular Center Essen), Phyllis F. Cheung(German Cancer Research Center), Lukas Kessler(German Cancer Research Center), Hanno Glimm(German Cancer Research Center), Fadi Zarrad(Essen University Hospital), Johanna Falkenhorst(Essen University Hospital), Jens T. Siveke(German Cancer Research Center), Margret Droste(German Cancer Research Center), Jennifer Hüllein(Heidelberg University), Merve Akbulut(Essen University Hospital), Ilektra A. Mavroeidi(Essen University Hospital), Daniel Hübschmann(German Cancer Research Center), Monika A. Miera(Essen University Hospital), Stefan Fröhling(German Cancer Research Center)
Cited by 26
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k